Adjuvant treatment of novel multiple cancer vaccine restricted with HLA-A24 for patients with completely resected non-small cell lung cancer. randomized phase II trial

Adjuvant treatment of novel multiple cancer vaccine restricted with HLA-A24 for patients with completely resected non-small cell lung cancer. randomized phase II trial - Adjuvant treatment of multiple cancer vaccine for patients with completely resected non-small cell lung cancer. randomized phase II trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009380

Enrollment

Registered

2012-12-01

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

multiple vaccine with Montanide ISA51 VG matched with HLA-A24 1. URLC10 (up regulated lung cancer 10,LY6K) 2. CDCA1 (cell division cycle associated 1) 3. VEGFR1 4. VEGFR2 multiple vaccine with Mo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmed stage IB-IV NSCLC 2)Completely resected NSCLC by lobectomy or more with lymph node dissection 3)Age of 20 years or older 4)ECOG performance status 0-1 5)With adequate major organ functions as defined below: *White blood cell count 1,500-15000/mm3 *Platelet count >= 75,000/mm3 *AST <= 3 times institutional normal range *ALT <= 3 times institutional normal range *Creatinine <= 2 times institutional normal range 6) Be able to start within 4 week after surgery in patients without adjuvant chemotherapy treatment and within 6 week after adjuvant chemotherapy 7)Written informed consent

Exclusion criteria

Exclusion criteria: 1. With uncontrollable ischemic heart disease and/or arhythmia 2. With acute myocardial infarction 6 months before treatment 3. Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 4. With double cancer, multiple cancer 5. With active inflammatory disease 6. With steroidal or immunosuppressive agent dependency 7. Physician concludes that the patient's participation in this trial is inappropriate

Design outcomes

Primary

Measure	Time frame
Recurrence free survival	—

Secondary

Measure	Time frame
Overall survival Antigen specific T cell responses	—

Countries

Japan

Contacts

Public ContactSUZUKI Hiroyuki

Fukushima Medical University Chest Surgery

hiro@fmu.ac.jp024-547-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026